about
Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo.Target Therapies for Uterine Carcinosarcomas: Current Evidence and Future Perspectives.Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivoT-DM1, a novel antibody-drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo.Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivoT-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2.Clostridium perfringens enterotoxin (CPE) and CPE-binding domain (c-CPE) for the detection and treatment of gynecologic cancersClostridium perfringens enterotoxin C-terminal domain labeled to fluorescent dyes for in vivo visualization of micrometastatic chemotherapy-resistant ovarian cancerPolymerase ε (POLE) ultra-mutated tumors induce robust tumor-specific CD4+ T cell responses in endometrial cancer patients.Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo.Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitroDual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo.PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas.Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro.Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivoMutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition.The role of novel biomarker HE4 in the diagnosis, prognosis and follow-up of ovarian cancer: a systematic review.Efficacy of neratinib in the treatment of HER2/neu-amplified epithelial ovarian carcinoma in vitro and in vivo.Dual-Targeting Nanoparticles for In Vivo Delivery of Suicide Genes to Chemotherapy-Resistant Ovarian Cancer Cells.SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression.Ten years of HPV vaccines: State of art and controversies.Validation of REM score to predict endometrial cancer in patients with ultrasound endometrial abnormalities: results of a new independent dataset.Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitroNeratinib shows efficacy in the treatment of HER2/neu amplified uterine serous carcinoma in vitro and in vivo.Undescended or absent ovary without uterine anomalies: systematic review and a single-center experience.Further insight into prognostic factors in endometrial cancer: the new serum biomarker HE4.HER2/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitor.Undescended or absent ovary without uterine anomalies: systematic review and a single center's experience.Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2).Role of paroxetine in the management of hot flashes in gynecological cancer survivors: Results of the first randomized single-center controlled trial.Antiangiogenics and immunotherapies in cervical cancer: an update and future's view.Hemorrhagic cystitis in pregnancy: Case report and review of the literature.May intraperitoneal irrigation with Betadine improve cesarean delivery outcomes? Results of a 6 years' single centre experience.A Predictive Score for Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer (SeC-Score): A Single-Centre, Controlled Study for Preoperative Patient Selection.Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro.Anterior colporrhaphy plus inside-out tension-free vaginal tape for associated stress urinary incontinence and cystocele: 10-year follow up results.The Role of HE4, a Novel Biomarker, in Predicting Optimal Cytoreduction After Neoadjuvant Chemotherapy in Advanced Ovarian Cancer.Hormone replacement therapy in cancer survivors: Utopia?Patients treated with neoadjuvant chemotherapy + radical surgery + adjuvant chemotherapy in locally advanced cervical cancer: long-term outcomes, survival and prognostic factors in a single-center 10-year follow-up.Implementing the Risk of Endometrial Malignancy Algorithm (REM) adding obesity as a predictive factor: Results of REM-B in a single-center survey.
P50
Q27853078-3B0F8E6F-69CD-46E8-A89F-19EBB253BE9AQ33755476-079B183D-B82C-4E33-B315-4470A47A2F83Q34729807-3651E2B9-75F5-4D85-BA81-0387249480B1Q34998509-98D27CE5-07D4-4539-B5C8-572BEA3CAFB8Q35007586-EE3C9346-63C9-4009-ABE1-6F595CB50EDDQ35027806-ADC3AFC4-62CF-4E97-9B60-B191B8784659Q35564030-FF0EBA72-D311-483B-A47A-C354969BBE61Q35659378-A9FD7DD7-F10B-4514-A4F0-B842430E1F29Q35748591-8D79B7D8-8FB5-4BDE-ABAD-904810F90CECQ36103790-1419727E-5958-42AA-8453-4D32E66A2BA8Q36171935-B6632593-175A-481F-9AC1-7E601B8EBF88Q36258125-FBC5DD2F-466C-41F0-86FF-6F32EC20A4B4Q36295013-5118CAF5-E123-4BA7-A443-E2CF895CFB07Q36421292-810A9479-D1D5-48A8-9D62-C137B208F40BQ37151091-EFFAE2CD-B16A-4F06-A9BD-85A4F47B611EQ37379877-43984B1B-21AB-4C0D-84B1-1DA1075EB79AQ38653169-E53D5379-E764-499C-8C80-389DD3AE90FEQ38708134-40B164C7-0581-4FF3-851E-E0D30E633A84Q38726540-2DE7FC13-316C-4F66-A5D9-4478EF4E243CQ38766901-F62498CD-1885-43A5-ABAC-E27B26581A0BQ38804950-BCDA4AFE-A437-45E0-8DEB-16E2D04984F0Q38846968-F228F3F6-D65D-4D76-960D-B6EFE6FFE4F9Q38911022-B2C0376C-EE62-43CC-A17A-D46E65A77CAAQ38965974-0C09E527-9998-405C-B9BD-6E80DC1F2911Q38977979-0A6D1523-951C-4D54-A348-9AC4F9D25C9EQ39021988-934DDBE4-63AC-484A-875F-6AD7C17E01CBQ39098938-3A9A7F11-F8A2-4022-8AD2-BF73E409A56FQ39100294-55DE594D-2B40-4D84-A3F6-8EDA3DE8AE72Q39119683-D0F5EC63-CAE2-4FEE-9A2C-4E875837B401Q39280580-24D2256D-1C46-4615-9D2B-20A20B966BA9Q39287099-390EB624-0578-4EE5-9BFB-53E7C7128364Q40064888-8610AD31-E613-4067-A05C-C0578993ED6FQ40066241-967B40B2-C4C9-49DE-B428-ABAEE684D7DDQ41161911-71748CE6-016F-451F-BEBA-D3C16A24D8D3Q47104826-9E1C87BE-DF10-43FF-A22F-8580396CF834Q48145998-63E1C0B6-1001-4D4C-85EC-9EA214EAB416Q48665253-675621A8-0477-4FC2-BB79-B3C8A9786EFFQ51739185-1F1AE1E8-B7EF-4135-9C39-B9502ADD132BQ51830795-4DD1B4ED-18FF-416D-837A-BC90E4132A10Q52585449-4D645A4B-18DB-4DF6-8CD2-B57EA66C53A5
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Salvatore Lopez
@ast
Salvatore Lopez
@en
Salvatore Lopez
@es
Salvatore Lopez
@nl
Salvatore Lopez
@sl
type
label
Salvatore Lopez
@ast
Salvatore Lopez
@en
Salvatore Lopez
@es
Salvatore Lopez
@nl
Salvatore Lopez
@sl
prefLabel
Salvatore Lopez
@ast
Salvatore Lopez
@en
Salvatore Lopez
@es
Salvatore Lopez
@nl
Salvatore Lopez
@sl
P106
P1153
55832921900
P21
P31
P496
0000-0001-7705-3715